Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Tax Provisions (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Tax Provisions for 4 consecutive years, with $166000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Tax Provisions fell 72.7% to $166000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $3.4 million, a 15.42% increase, with the full-year FY2024 number at $2.8 million, up 111.35% from a year prior.
  • Tax Provisions was $166000.0 for Q3 2025 at Centessa Pharmaceuticals, down from $778000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $1.4 million in Q1 2025 to a low of -$24.1 million in Q2 2023.
  • A 4-year average of -$1.4 million and a median of $481000.0 in 2024 define the central range for Tax Provisions.
  • Biggest YoY gain for Tax Provisions was 746.25% in 2023; the steepest drop was 109222.73% in 2023.
  • Centessa Pharmaceuticals' Tax Provisions stood at -$664000.0 in 2022, then skyrocketed by 272.29% to $1.1 million in 2023, then fell by 8.22% to $1.0 million in 2024, then tumbled by 84.19% to $166000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Tax Provisions are $166000.0 (Q3 2025), $778000.0 (Q2 2025), and $1.4 million (Q1 2025).